At Oxidien™, we are dedicated to bringing life-changing products to patients in need. We create best-in-class enzyme-based pharmaceuticals. Using innovative research, open-minded conviction, and passionate diligence Oxidien™ is committed to advancing the standard of care. The name Oxidien™ stems from the dietary culprit (oxalate) and the patient indications we serve: “Ox” for oxalate, “idi” for idiopathic and “en” for enteric.
Secondary hyperoxaluria is a disease with significant unmet medical need. Patients demonstrate wide ranging severity, from manageable symptoms to severe and chronic complications. There are two types of Secondary (2°) Hyperoxaluria : Idiopathic Hyperoxaluria (IH) and Enteric Hyperoxaluria (EH) 1, 2, 3.
- IH is the most common type, and mostly observed in individuals with calcium oxalate kidney stones 1, 4, 5 .
- EH is partly caused by an underlying gastrointestinal complication associated with a malabsorption of oxalate. In these patients, oxalate becomes more available for absorption 2 , which can cause severe kidney damage and can lead to end-stage renal failure.
OX-1 is a novel oxalate decarboxylase (OxDC) enzyme developed with the support of multiple National Institute of Health (NIH) Small Business Innovation Research (SBIR) Grants. OX-1 demonstrates stability in a wide pH range including very acidic environments; thus, can effectively degrade oxalate in the gastrointestinal tract, in particular the stomach.
A Prospective, Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study Utilizing Orally Administered Oxalate Decarboxylase (OxDC) To Reduce Urinary Oxalate
In Vitro And In Vivo Safety Evaluation of Ox-1
AA-1 (also known as A0) is an oxalate decarboxylase (OxDC) enzyme originating from a fungal source. AA-1 has the potential to degrade oxalate throughout the complete gastrointestinal tract due to its extremely wide pH activity profile with activity in neutral and basic pH range.
Urinary Oxalate by Enzymatic Reduction of Dietary and Endogenous Oxalate, an abstract and poster featuring research partner, Captozyme, and their A0 research.
Chief Executive Officer
Chief Financial Officer
Ira W. Klimberg
Chief Medical Officer
BSBA, CCRP, CCRA
Director of Clinical Research
Meet Us Here
For details on what we are up to and where we are, please check out our Events and Presentations page.